Abstract
This editorial reviews a recently published guideline on management of irritable bowel syndrome. The guideline illustrates problems arising from the quality of clinical trials used in systematic reviews and the potential impact of the inherent weaknesses of those trials on rating the strength of evidence and the resulting recommendations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 629-632 |
| Number of pages | 4 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 16 |
| Issue number | 5 |
| DOIs | |
| State | Published - Apr 1 2015 |
Keywords
- American college of gastroenterology
- Evidence
- GRADE
- Guidelines
- Irritable bowel syndrome
- Medications
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)